XML 64 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
Quarterly Financial Information (Unaudited)
 12 Months Ended
Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Information (Unaudited)
Quarterly Financial Information (Unaudited)
The following is a summary of the quarterly results of operations of the Company for the years ended December 31, 2013 and 2012 (unaudited):
 
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
December 31,
2013
 
September 30,
2013
 
June 30,
2013
 
March 31,
2013
Consolidated Statements of Operations:
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
Revenue under collaborative research and development arrangements
$
822,217

 
$
8,388,760

 
$
14,311

 
$
14,259

Revenue under collaborative research and development arrangements with affiliated entity
106,250

 
106,250

 
106,250

 
106,250

Grants and miscellaneous revenue
811,199

 
991,835

 
665,049

 
1,334,716

Total revenues
1,739,666

 
9,486,845

 
785,610

 
1,455,225

Operating Expenses:
 
 
 
 
 
 
 
Research and development
6,404,005

 
5,438,405

 
4,411,082

 
5,115,112

General and administrative
4,339,539

 
3,282,796

 
3,046,586

 
2,974,153

Gain on sale of assets
(1,000,000
)
 
—

 
(1,000,000
)
 
—

Total operating expenses
9,743,544

 
8,721,201

 
6,457,668

 
8,089,265

Loss from operations
(8,003,878
)
 
765,644

 
(5,672,058
)
 
(6,634,040
)
Interest and other income, net
8,576

 
46,787

 
37,391

 
39,460

Change in fair value of common stock warrants
(6,052,965
)
 
(34,952,210
)
 
(3,199,878
)
 
(1,427,616
)
(Loss) Gain from investment in affiliated entity
(1,419,536
)
 
3,248,926

 
(2,032,051
)
 
(836,084
)
Net loss
(15,467,803
)
 
(30,890,853
)
 
(10,866,596
)
 
(8,858,280
)
Net loss attributable to non-controlling interest
13,473

 
13,443

 
14,008

 
14,160

Net loss attributable to Inovio Pharmaceuticals, Inc.
$
(15,454,330
)
 
$
(30,877,410
)
 
$
(10,852,588
)
 
$
(8,844,120
)
Loss per common share—basic and diluted:
 
 
 
 
 
 
 
Net loss attributable to Inovio Pharmaceuticals, Inc. stockholders
$
(0.07
)
 
$
(0.16
)
 
$
(0.06
)
 
$
(0.06
)
Weighted average number of common shares—basic and diluted
208,509,676

 
191,956,155

 
179,954,816

 
156,155,532



 
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
December 31,
2012
 
September 30,
2012
 
June 30,
2012
 
March 31,
2012
Consolidated Statements of Operations:
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
Revenue under collaborative research and development arrangements
$
14,296

 
$
22,495

 
$
20,907

 
$
24,838

Revenue under collaborative research and development arrangements with affiliated entity
142,483

 
222,484

 
106,250

 
106,250

Grants and miscellaneous revenue
977,974

 
609,717

 
308,925

 
1,562,033

Total revenues
1,134,753

 
854,696

 
436,082

 
1,693,121

Operating Expenses:
 
 
 
 
 
 
 
Research and development
4,442,841

 
4,972,319

 
4,527,086

 
4,042,579

General and administrative
2,919,000

 
2,674,362

 
2,696,909

 
2,488,088

Gain on sale of assets
—

 
(500,000
)
 
—

 
(651,000
)
Total operating expenses
7,361,841

 
7,146,681

 
7,223,995

 
5,879,667

Loss from operations
(6,227,088
)
 
(6,291,985
)
 
(6,787,913
)
 
(4,186,546
)
Interest and other income, net
56,520

 
37,013

 
41,036

 
31,544

Change in fair value of common stock warrants
3,049,649

 
(1,113,638
)
 
3,594,782

 
(3,548,173
)
Gain (Loss) from investment in affiliated entity
2,449,615

 
736,121

 
(992,373
)
 
(561,544
)
Net loss
(671,304
)
 
(6,632,489
)
 
(4,144,468
)
 
(8,264,719
)
Net loss attributable to non-controlling interest
12,553

 
10,413

 
11,289

 
9,770

Net loss attributable to Inovio Pharmaceuticals, Inc.
$
(658,751
)
 
$
(6,622,076
)
 
$
(4,133,179
)
 
$
(8,254,949
)
Loss per common share—basic and diluted:
 
 
 
 
 
 
 
Net loss attributable to Inovio Pharmaceuticals, Inc. stockholders
$
—

 
$
(0.05
)
 
$
(0.03
)
 
$
(0.06
)
Weighted average number of common shares—basic and diluted
140,704,889

 
135,389,308

 
134,968,394

 
134,968,394